Bako Diagnostics Responds to Recent Statements Made by Dr. Bradley Bakotic

ATLANTA. Jun. 26, 2018 – At Bako Diagnostics, among our highest priorities are upholding the quality and integrity of our work, maintaining the utmost professional standards, and ensuring that our company provides a safe workplace for our employees. As a result of false and misleading public statements being made by our former CEO, Dr. Bradley Bakotic, we now find it necessary to clarify the facts of his termination from Bako Diagnostics in an equally-public manner.

Dr. Bakotic was terminated from Bako Diagnostics on September 8, 2017 after allegations of misconduct were made against him and following a comprehensive, independent investigation conducted by the company’s outside counsel, Latham & Watkins. During this investigation, Dr. Bakotic admitted to instances of misconduct including sexual relationships with subordinate female employees, as well as physically assaulting one of the female employees with whom he was having an ongoing relationship. Latham & Watkins also received multiple allegations of illegal drug use by Dr. Bakotic, which they found to be credible. As a result, a Special Committee of the Board of Bako Diagnostics saw no other choice but to terminate Dr. Bakotic’s employment.

We find Dr. Bakotic’s alteration of these facts and proclamations of his innocence, particularly after his admission to the assault, to be disingenuous and potentially damaging to the reputation of Bako Diagnostics and its employees. The facts speak for themselves and are clearly described and outlined in legal filings.

We wish to set the record straight and focus our attention on delivering the highest quality laboratory services and products for our valued clients. We are confident in the merits of our case and look forward to our day in court when Bako Diagnostics can continue without these distractions.


Bako Diagnostics is a provider of diagnostic and therapeutic services for the Podiatric Medical Community with a unique focus on pathology of the lower extremity. Bako’s comprehensive testing menu includes ENFD Analysis, Mass Spectrometry, for rapid identification of bacteria from culture specimens, and Molecular Genetics for the detection of micro-organisms and as a diagnostic aid in certain pathologic diagnoses. Bako’s in-network services are available through its more than 250 million covered lives, including all five national health plans and fully compliant patient-friendly billing policies.  Over the past nine years, Bako has evolved into one of the podiatric profession’s principal sources of educational sponsorship.

Onychodystrophy Molecular Assay now includes Pseudomonas aeruginosaLEARN MORE
+ +